Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study Meeting Abstract
| Authors: | Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; Gabayan, A. E.; Stevens, D. A.; Nooka, A. K.; Raje, N.; Iida, S.; Leip, E.; Conte, U.; Czibere, A.; Viqueira, A.; Lesokhin, A. M. |
| Abstract Title: | Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | clinical trial; phase ii; mm; bispecific; b-cell maturation antigen |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S493 |
| End Page: | S494 |
| Language: | English |
| ACCESSION: | WOS:001062479600574 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01443-X |
| Notes: | Meeting Abstract: MM-364 -- Source: Wos |
